Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (174168)	7/4/2021 7:02:26 AM
From: Julius Wong	Respond to of 217711

Deaths due to COVID-19 Delta variant among fully vaccinated: Scientists are not alarmed Jul. 03, 2021 9:14 PM ETBNTX, JNJ... By: Dulan Lokuwithana, SA News Editor 65 Comments jarun011/iStock via Getty Images The U.K., considered as a bellwether of the post-pandemic world, has recorded a small number of so-called breakthrough COVID-19 cases leading to questions over vaccine efficacy. According to Our World in Data, as of July 01, the U.K. has fully vaccinated nearly 49% of its population. Approximately 66% of people have received at least one COVID-19 shot. However, the country is caught up in an uptick in case numbers as the highly transmissible Delta variant spread accounting for 146K identified cases over the past week, up 72% from a week ago. Currently, the prevalence of the Delta variant in the U.K. stands at 97%. There were 117 deaths among 92K Delta variant cases recorded through June 21. And 50 of those who died have received the two doses of the COVID-19 vaccine, The Wall Street Journal reported citing data from Public Health England. Yet, the scientists are not sounding the caution as they point out that none of the vaccines authorized by regulators are 100% effective in the prevention of COVID-19. Furthermore, the immune responses of different individuals vary. The elderly and those who have a weaker immune system are less likely to mount a strong immune response as might be expected from younger and healthier individuals. The other reason: Even if the vaccination cuts the COVID-related risk of death by 95% in the elderly, the mortality risk of a fully immunized elderly person might still be higher than that faced by a much younger person even with no vaccination against COVID-19. According to data from the U.K., all 50 Delta-variant-related deaths reported among fully vaccinated people were in those aged 50 years and older. Based on late-stage studies, the messenger-RNA-based vaccines from Pfizer (NYSE: PFE)/BioNTech (NASDAQ: BNTX) and Moderna (NASDAQ: MRNA) had about 95% efficacy in the prevention of COVID-19. Meanwhile, the vector-based shots from Johnson & Johnson (NYSE: JNJ) and AstraZeneca (NASDAQ: AZN) showed 66% and ~70% overall efficacy levels, respectively. seekingalpha.com